A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64% in the DE111 group, while the proportion of normal stools decreased from 56% to 48% in the placebo group. In male participants specifically, the proportion of normal stools increased from 56% to 80%. In addition, a significant difference between the DE111 and placebo groups was observed in regards to normal and non-normal stool proportions in the 30+ age group.
In a study involving 44 participants aged 20-62, researchers observed after four weeks of daily consumption of the probiotic DE111…More
KENNESAW, GA (August 2, 2021) - Deerland Probiotics & Enzymes has announced the publication of a new study that is…More
Collective research on the genetic and mechanistic abilities of the probiotic DE111® has been published in Frontiers of Microbiology. This…More